Berdazimer
DERMATOLOGICALS
Also known as: berdazimer sodium, NVN1000, SB206, zelsuvmi
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Berdazimer is a drug catalogued in DrugCentral. It was first approved by the FDA in 2024. Recorded indications include Infection caused by Molluscum contagiosum.
- Indications: Infection caused by Molluscum contagiosum.
- ATC code: D06BB13 (Antivirals).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Infection caused by Molluscum contagiosum
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2024-01-05 | FDA | — | Ligand Pharmaceuticals (LNHC) |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
D06BB13 | DERMATOLOGICALS › ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE › CHEMOTHERAPEUTICS FOR TOPICAL USE › Antivirals |
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | — |
| InChIKey | — |
| PubChem CID | — |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Berdazimer used for?
DrugCentral lists the following indications for Berdazimer: Infection caused by Molluscum contagiosum.
When was Berdazimer first approved?
Berdazimer was first approved by the FDA in 2024.
Browse: all drugs starting with B · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5860 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL4298064 — compound record and bioactivity
- FDA UNII ORT9SID4QY — substance identity
- DailyMed: FDA labels for Berdazimer — current prescribing information (label search)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.